Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $64 | In Stock | |
10 mg | $97 | In Stock | |
25 mg | $226 | In Stock | |
50 mg | $336 | In Stock | |
100 mg | $491 | In Stock | |
500 mg | $1,090 | In Stock | |
1 mL x 10 mM (in DMSO) | $70 | In Stock |
Description | IMS2186 is a reagent with activity of antichoroidal neovascularization (CNV). IMS2186 could arrest cancer cell cycle in G2/M phase, result in exerting anti-proliferation and anti-angiogenesis effects. IMS2186 reduces the amount of eye leakage and diseased cells with no intraocular toxicity. |
In vitro | IMS2186 (0.3-10 μM; 22 h) inhibits the proliferation of human fibroblasts and human cancer cells with IC50 of 1.0-3.0 μM, 0.3-3.0 μM, respectively. IMS2186 (0-10 μM; 22 h) inhibits the formation of endothelium with IC50 of 0.1-0.3 μM under the stimulation of 10 ng/mL VEGF. IMS2186 (0.1-10 μM; 24 h) inhibits the production of pro-inflammatory cytokine PGE2/TNF-a in macrophages with IC50 of 0.3-1 μM. IMS2186 (0.1-10 μ M; 1.5 h) inhibits migration of macrophage with IC50 of 1 μM[1]. |
In vivo | IMS2186 (2.5 mg in 0.5 mL; vitreous injection; single dose) was administered to rabbit eyes with no ocular toxicity. IMS2186 (100 μg/eye, i.e. 50 μg/μL solution dosage 2.0 μ L; Single dose) exhibited anti-proliferative effect on the rat model of laser-induced choroidal neovascularization (CNV) [1]. |
Molecular Weight | 296.32 |
Formula | C18H16O4 |
Cas No. | 1031206-36-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 60 mg/mL (202.48 mM) ![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.